Study to Assess the Efficacy, Safety and Tolerability of MT- 8554 in Subjects With Painful Diabetic Peripheral Neuropathy

Inclusion Criteria: * Male subjects and female subjects aged ≥18 years * Subjects who have a history of pain at least 6 months and ≤7 years attributed to diabetic peripheral neuropathy * A body mass index ranging from 18 to 45 kg/m2 Exclusion Criteria: * Subjects who have participated in a clinical study of any IMP (other than placebo) within 12 weeks (from last administration) prior to screening or who are currently participation in another clinical study * Unstable or uncontrolled diabetes * Clinically significant 12-lead ECG abnormalities